The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 19, 2017

Filed:

Jul. 11, 2011
Applicants:

Christelle Bolea, Geneva, CH;

Sylvain Celanire, Geneva, CG;

Lam Tang, Geneva, CH;

Nigel J. Liverton, Harleysville, PA (US);

Philip Jones, Houston, TX (US);

Inventors:

Christelle Bolea, Geneva, CH;

Sylvain Celanire, Geneva, CG;

Lam Tang, Geneva, CH;

Nigel J. Liverton, Harleysville, PA (US);

Philip Jones, Houston, TX (US);

Assignees:

Addex Pharma S.A., Geneva, CH;

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 513/12 (2006.01); A61K 31/4162 (2006.01); A61K 31/429 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01); C07D 513/04 (2006.01); C07D 513/14 (2006.01); A61K 31/433 (2006.01); A61K 31/4439 (2006.01); A61K 31/506 (2006.01); A61B 5/00 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/10 (2006.01); A61K 9/20 (2006.01); A23L 5/00 (2016.01);
U.S. Cl.
CPC ...
C07D 513/12 (2013.01); A23L 5/00 (2016.08); A61B 5/00 (2013.01); A61K 9/0019 (2013.01); A61K 9/0095 (2013.01); A61K 9/06 (2013.01); A61K 9/10 (2013.01); A61K 9/2059 (2013.01); A61K 31/429 (2013.01); A61K 31/433 (2013.01); A61K 31/4439 (2013.01); A61K 31/506 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); C07D 513/04 (2013.01); C07D 513/14 (2013.01);
Abstract

The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 ('mGluR') which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluRreceptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluRis involved.


Find Patent Forward Citations

Loading…